Cynthia L. Meyer is a partner who joined the firm in 2011 and practices primarily in food and drug law and advertising law.  She regularly provides counsel and advocates on behalf of clients in the pharmaceutical, dietary supplement, food, medical device, cosmetic, cannabis/hemp, and consumer product industries on legal and regulatory matters involving the U.S. Food and Drug Administration (FDA), Federal Trade Commission (FTC), U.S. Department of Agriculture (USDA), the U.S. Consumer Product Safety Commission (CPSC), and other related federal and state agencies.  Ms. Meyer works with clients to understand their goals and assist them in strategically navigating the legal and regulatory landscape relevant to their business, throughout the product life cycle.

Selected matters include:

  • Serving as the legal representative on client’s Promotional Review Committees (PRCs or MLRs) for prescription drug brands
  • Counseling on all aspects of advertising and marketing of drugs, dietary supplements, food, and cosmetics, including labeling and claims review
  • Advising on the current legal and regulatory status of hemp and CBD in FDA regulated products
  • Assessing potential applicability of over-the-counter (OTC) drug monograph to proposed product formulation and dosage form, labeling requirements, and whether proposed claims are consistent with any applicable monograph
  • Advising on compliance with the Dietary Supplement Health and Education Act of 1994, including assessing the regulatory status of ingredients and whether a new dietary ingredient notification is required, advising on appropriate structure-function claims, and reviewing claims substantiation
  • Assisting clients with responding to complaints or inquiries from or before FDA, the FTC, the National Advertising Division of the Council of Better Business Bureaus (NAD), or similar entities
  • Assessing the regulatory status of a potential medical device, including whether the product would require 510(k) or PMA submission or could be considered a general wellness device or laboratory developed test (LDT)
  • Corresponding with FDA on behalf of the client to facilitate release of import entries subject to FDA hold
  • Preparing and submitting successful petition for removal from Import Alert Detention Without Physical Examination (DWPE or “Red List”) status
  • Advising on cGMP issues, FDA inspections, and recalls
  • Reviewing and drafting proposed legislative language or comments to proposed FDA regulations or guidance

 

Selected prior speaking engagements include:

  • “Working Group on Substantiating Advertising Claims for FDA Regulated Consumer Products: OTC Drugs, Food, Dietary Supplement and Cosmetics.” Panelist. Post-Conference Workshop. ACI Advertising Claims Substantiation Legal, Regulatory and Compliance Forum. 30 January 2020 (New York, NY).
  • “Case Study on Pharmaceutical Advertising and Promotion.” Panelist. FDLI Advertising and Promotion for Medical Products Conference. 17 October 2019 (Washington, DC).
  • “GRAS/NDI Workshop, Module 1.” Speaker. AHPA Hemp-CBD Supplement Congress. 15 August 2019 (Denver, CO).
  • “Clarifying the Legal Pathway for Hemp-Derived CBD in Food and Dietary Supplements.” Panelist. ACI Dietary Supplement Regulatory and Compliance Forum. 18 June 2019 (New York, NY).

 

Prior to joining the firm, Ms. Meyer worked as a biologist at the National Cancer Institute at NIH. She received her B.S. in Biology from Duke University and her J.D. from Georgetown University Law Center.